Valganciclovir

Valganciclovir is a medicine used to fight infections caused by Cytomegalovirus (CMV). It's often given to people with weakened immune systems, like those with AIDS or after an organ transplant. It's a type of antiviral drug.

Brand names:Valcyte
Medication

What people taking Valganciclovir report

Every report comes from a Lived member, sent anonymously.

Have you tried Valganciclovir for CMV?

NameHow it went

About Valganciclovir

What It's For

Valganciclovir, sold as Valcyte and as generics, is a prescription antiviral used against cytomegalovirus (CMV). CMV is a common herpes-family virus that most healthy people carry without trouble, but it can cause serious disease when the immune system is weakened, for example by advanced HIV (human immunodeficiency virus) infection or by the medicines that prevent rejection of a transplanted organ. It has two approved uses. In adults with AIDS (acquired immunodeficiency syndrome, the advanced stage of HIV infection), it treats CMV retinitis, an infection of the retina at the back of the eye that can lead to blindness. After a kidney, heart or kidney-pancreas transplant, it prevents CMV disease in people at high risk, mainly those who have never had CMV themselves but received an organ from a donor who had. Children who receive a kidney or heart transplant can also take it for prevention. Transplant teams also use it more broadly, both to treat CMV infections and to treat early when routine blood tests show the virus rising, and specialists sometimes prescribe it for newborns born with symptomatic CMV infection. These uses fall outside the label but are well established in specialist care.

How It Works

Valganciclovir is a prodrug, meaning it is an inactive form that the body converts into the active medicine. Soon after it is swallowed, the gut and liver turn it into ganciclovir, an older CMV drug that otherwise has to be given by vein. Taking the pill form lets many people get the same treatment at home. Inside a cell infected with CMV, an enzyme made by the virus itself starts activating ganciclovir. Because this activation depends mostly on the virus, the drug builds up mainly in infected cells. The activated form then blocks the enzyme CMV uses to copy its genetic material, so the virus cannot multiply. It stops the virus from spreading rather than eliminating it, which is why it controls CMV but does not cure it. Rapidly dividing healthy cells, especially in the bone marrow, are also somewhat sensitive to the drug, which explains its main side effects.

Dosage & Administration

Adults take valganciclovir as 450 mg tablets, usually two tablets at a time. For CMV retinitis, treatment starts with a higher twice-daily dose for about three weeks to bring the infection under control, then continues once a day. For prevention after a transplant, it is usually taken once a day, starting within 10 days of the operation and continuing for about 100 days after a heart or kidney-pancreas transplant, or 200 days after a kidney transplant. Children take a liquid form, with a dose calculated from their size and kidney function; adults should use the tablets rather than the liquid. Take it with food, which helps the body absorb it. Swallow the tablets whole without breaking or crushing them. Because the drug may harm a developing baby and is considered a possible cause of cancer, avoid touching broken tablets or the liquid; if it gets on skin or in the eyes, wash with soap and water or rinse the eyes with plain water. The kidneys clear the drug, so the dose is lowered when kidney function is reduced and blood tests of kidney function are repeated during treatment. Drinking enough fluids helps protect the kidneys. Do not stop early without talking to the prescriber, since stopping too soon can let the virus rebound or become resistant.

Side Effects

Diarrhea, nausea, vomiting, fever, tiredness, headache, trouble sleeping and a mild tremor are among the most common effects. Many people taking valganciclovir are also recovering from a transplant or living with advanced HIV, so it is not always clear which symptoms come from the medicine. The most important risk is lowered blood counts. Valganciclovir can reduce white blood cells (which fight infection), red blood cells (which carry oxygen) and platelets (which help blood clot), and in rare cases it can cause bone marrow failure. This can happen at any point during treatment, which is why frequent blood tests are part of taking it. When the drug is stopped, counts usually begin to recover within three to seven days. Contact the care team right away for fever, chills, a sore throat or other signs of infection; unusual bleeding or bruising; or new paleness, unusual tiredness, shortness of breath or a fast heartbeat. The kidneys can also be affected, especially in older adults, people who are dehydrated and people taking other medicines that strain the kidneys. Passing much less urine or seeing blood in the urine should be reported promptly. Seizures, dizziness and confusion have been reported, so it is sensible to see how you react before driving. People treated for CMV retinitis should call their eye doctor promptly for new specks, flashes of light or a dark curtain across their vision, which can signal a detached retina or worsening infection.

Interactions & Warnings

Valganciclovir carries a boxed warning, the most prominent warning the US Food and Drug Administration requires, covering four risks. Besides lowered blood counts, it may cause birth defects and it may cause temporary or permanent infertility in both men and women. In animal studies it caused cancer, so it is treated as a possible cause of cancer in people, although that risk has not been measured in humans. Because of the pregnancy risk, women who could become pregnant should use effective birth control during treatment and for at least 30 days after the last dose, and men should use condoms during treatment and for at least 90 days after. Anyone who becomes pregnant while taking it should contact their prescriber right away. Breastfeeding is not recommended during treatment. People who hope to have children in the future can raise fertility concerns with the team before starting. The most important interactions involve medicines that also suppress the bone marrow or strain the kidneys, because the effects add up. After transplant this often includes mycophenolate (CellCept), an anti-rejection medicine that can also lower blood counts, and cyclosporine or tacrolimus, anti-rejection medicines that can affect the kidneys; these are often used together on purpose, with closer monitoring. The antibiotic imipenem-cilastatin is generally avoided because seizures have occurred with the combination. People who have had a serious allergic reaction to ganciclovir should not take valganciclovir. Keep the transplant or HIV team and the pharmacist informed of every new prescription.

What to Expect

For transplant prevention, valganciclovir is a fixed course rather than an open-ended treatment. The usual course covers roughly the first 100 or 200 days after surgery, depending on the organ, a period when CMV is a common problem for transplant recipients. Some transplant centers instead check blood for CMV regularly and start treatment only if the virus appears. CMV can still emerge after the preventive course ends, so blood tests or symptom checks often continue afterward. For CMV retinitis, the drug controls the infection but does not cure it, and the retina can still worsen during or after treatment. Eye exams at least every four to six weeks are part of care, and long-term control depends heavily on restoring the immune system with effective HIV treatment. Whatever the reason for taking it, expect frequent blood tests for blood counts and kidney function. If counts fall, the team may lower the dose, pause it, add a medicine that helps the bone marrow make white cells, or switch to another antiviral. For high-risk kidney transplant recipients, letermovir (Prevymis), a different CMV antiviral, is an approved alternative for prevention; in its main trial, people stopped it because of side effects less often than they stopped valganciclovir.

Questions to Ask Your Doctor

  1. 1.Why is valganciclovir recommended for me, and would letermovir or a monitor-and-treat approach be reasonable alternatives?
  2. 2.How long will I take it, and how will we check for CMV after the course ends?
  3. 3.How often will my blood counts and kidney function be tested, and what happens if my counts drop?
  4. 4.Which of my other medicines, including anti-rejection drugs, add to the risk of side effects?
  5. 5.What do the fertility and pregnancy warnings mean for my family plans, and how long should birth control continue after I stop?

Last reviewed • Oct 2026

Educational content, not medical advice.